The UK Interventional Radiology Devices market was valued at USD 968.5 Million in 2025 and is projected to reach USD 2,123.7 Million by 2035, growing at a CAGR of 7.8% from 2024 to 2035. Driven by increasing chronic disease prevalence and adoption of minimally invasive procedures, the market presents significant growth opportunities for device manufacturers and healthcare providers.
The economic impact of tariffs on "UK Interventional Radiology Devices".
UK Interventional Radiology Devices Market Growth Drivers
Rising Prevalence of Chronic Diseases: Increasing cases of cardiovascular diseases, cancer, and peripheral vascular disorders in the UK are fostering demand for interventional radiology devices. For example, Siemens Healthineers has reported heightened demand for its advanced angiography systems and image-guided therapy solutions as hospitals seek minimally invasive interventions to address chronic conditions, ultimately reducing hospital stay and improving patient outcomes.
Technological Advancements and Product Innovation: The launch of next-generation devices and improved imaging modalities is accelerating growth in the market. Companies like Medtronic PLC are introducing smart catheters and drug-eluting devices with enhanced navigation and safety. These innovations aid clinicians in performing complex interventions with higher precision, thus increasing adoption across UK hospitals and outpatient centers.
UK Interventional Radiology Devices Market Trends
Expansion of Outpatient and Office-Based Labs: There is a notable rise in the implementation of interventional radiology services in ambulatory and office-based lab settings in the UK as healthcare providers aim to reduce hospital system burdens. Philips Healthcare has rolled out portable imaging equipment and compact intervention suites, enabling clinicians to perform procedures such as angioplasties and embolization outside traditional hospital environments, thereby enhancing access and reducing costs.
Integration of Artificial Intelligence (AI) in Imaging: Market leaders are integrating AI-based algorithms into imaging systems for better pre-procedural planning and real-time guidance. GE Healthcare has collaborated with NHS trusts in the UK to deploy AI-enabled digital imaging solutions, improving diagnostic accuracy, automating workflow, and enabling precise targeting during interventions. These advancements are helping clinicians minimize procedural time and complications, driving market adoption.
UK Interventional Radiology Devices Market Opportunities
Development of Novel Embolization Materials: There are promising opportunities for companies such as Boston Scientific to develop and commercialize innovative embolic agents targeted at treating UK cancer and uterine fibroid patients, driven by increasing preference for targeted, minimally invasive therapies.
Growing Collaborations with NHS and Private Sector: Strategic collaborations between device manufacturers and UK healthcare providers for training and technology integration, such as partnerships with the NHS, represent a key opportunity for expanding market reach and adoption.
UK Interventional Radiology Devices Market Revenue (USD Million), 2020-2035
The chart showcases a robust upward trajectory in UK Interventional Radiology Devices market revenue from 2020 to 2035. The market begins at USD 560 million in 2020 and demonstrates steady growth, surpassing USD 960 million by 2025. The subsequent decade is characterized by an amplified adoption of advanced radiology devices and minimally invasive procedures, driving revenues to nearly USD 2,123.7 million by 2035. This consistent growth is underpinned by technological advancements, rising chronic disease burden, and wider outpatient service adoption, solidifying the UK's status as a mature and rapidly evolving interventional radiology market.
UK Interventional Radiology Devices Market by Regions Share (%), 2025
The 2025 market share pie chart reveals that England dominates the UK Interventional Radiology Devices market, accounting for 66% of revenue, reflecting the region's expansive healthcare infrastructure and concentration of specialist centers. Scotland and Wales hold 14% and 10% respectively, attributed to ongoing investments in advanced medical technologies and regional healthcare programs. Northern Ireland represents 6%, while other smaller regions collectively make up 4%. This distribution demonstrates the pivotal role of centralized NHS initiatives, but also highlights emerging growth prospects across devolved regions as device utilization and skillsets expand.
UK Interventional Radiology Devices Recent Developments
In February 2024, Medtronic UK announced the NHS adoption of their new Onyx™ Frontier drug-eluting balloon catheter in select NHS trusts across London. The catheters are designed to treat peripheral artery disease more effectively and with fewer complications, aided by superior deliverability and advanced polymer coatings.
In January 2024, Philips Healthcare launched its new Azurion with FlexArm system in key UK hospitals, including the Royal Free Hospital in London. The system offers revolutionary image-guided therapy functionality for complex vascular interventions, enabling faster procedures, greater patient throughput, and improved patient safety.
In March 2024, Boston Scientific received UK MHRA clearance for its Interlock™-18 microcoils, expanding the company's embolization product portfolio in the UK. This development facilitates broader local access for clinicians performing minimally invasive vascular embolization for oncology and trauma patients, supporting more efficient and targeted procedures.
Press Releases